Bukwang Pharmaceutical Co., Ltd. (KRX: 003000)

Bukwang Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	117,598	151,227	85,517	82,777	79,291	37,585
Short-Term Investments	-	-	-	1,500	10,300	-
Cash & Short-Term Investments	117,598	151,227	85,517	84,277	89,591	37,585
Cash Growth	36.25%	76.84%	1.47%	-5.93%	138.37%	-62.56%
Accounts Receivable	23,393	35,729	87,950	90,428	103,675	102,803
Other Receivables	736.39	1,647	360.04	2,413	309.45	227.2
Receivables	24,129	37,376	88,310	92,842	103,985	103,030
Inventory	46,244	56,832	38,607	39,294	51,375	44,137
Prepaid Expenses	327.98	166.97	173.46	205.7	216.08	212.4
Other Current Assets	6,787	8,576	6,134	3,476	3,043	1,434
Total Current Assets	195,085	254,179	218,741	220,095	248,209	186,398
Property, Plant & Equipment	120,850	122,789	123,960	124,531	106,298	128,809
Long-Term Investments	21,945	31,626	35,132	36,963	34,189	53,000
Goodwill	-	878.73	834.51	828.7	827.05	796.77
Other Intangible Assets	4,846	9,177	6,157	6,151	6,172	9,585
Long-Term Accounts Receivable	-	-	-	-	-	8,045
Long-Term Deferred Tax Assets	0.71	-	-	3.63	7.27	-
Other Long-Term Assets	6,076	10,368	16,105	8,843	5,266	1,901
Total Assets	348,802	429,017	400,929	397,417	400,969	388,535
Accounts Payable	3,282	2,368	16,530	7,421	10,157	9,890
Accrued Expenses	-	2,978	1,755	1,776	2,055	1,748
Short-Term Debt	-	-	-	-	20,000	-
Current Portion of Leases	157.74	217.6	242.91	444.17	407.98	434.3
Current Income Taxes Payable	173.47	357.47	4,312	3,996	7,291	3,967
Other Current Liabilities	24,896	91,622	21,764	23,358	21,293	19,844
Total Current Liabilities	28,510	97,544	44,603	36,995	61,204	35,884
Long-Term Debt	78,868	78,525	-	-	-	-
Long-Term Leases	269.49	644.17	687.88	1,114	1,139	1,644
Long-Term Deferred Tax Liabilities	11,968	10,068	11,011	11,217	4,984	18,379
Other Long-Term Liabilities	217.93	7,971	72,780	68,030	62,450	4,558
Total Liabilities	119,832	194,752	129,082	117,356	129,778	62,049
Common Stock	36,402	36,402	36,402	36,402	33,289	31,766
Additional Paid-In Capital	8,240	4,808	6,800	7,357	7,071	27,203
Retained Earnings	170,147	225,783	258,585	264,703	273,253	310,441
Treasury Stock	-	-50,784	-50,784	-50,784	-50,268	-50,160
Comprehensive Income & Other	9,684	10,103	12,215	11,930	-4,846	6,996
Total Common Equity	224,473	226,311	263,217	269,608	258,499	326,246
Minority Interest	4,496	7,953	8,630	10,453	12,692	239.78
Shareholders' Equity	228,970	234,265	271,847	280,061	271,191	326,486
Total Liabilities & Equity	348,802	429,017	400,929	397,417	400,969	388,535
Total Debt	79,295	79,387	930.79	1,558	21,547	2,078
Net Cash (Debt)	38,303	71,840	84,586	82,719	68,044	35,507
Net Cash Growth	-31.00%	-15.07%	2.26%	21.57%	91.64%	-64.63%
Net Cash Per Share	559.46	1049.46	1235.65	1208.27	991.46	495.44
Filing Date Shares Outstanding	68.45	68.45	68.45	68.45	62.25	65.13
Total Common Shares Outstanding	68.45	68.45	68.45	68.45	68.48	70.4
Working Capital	166,575	156,634	174,138	183,101	187,005	150,514
Book Value Per Share	3279.15	3306.00	3845.13	3938.48	3775.04	4634.29
Tangible Book Value	219,627	216,255	256,226	262,628	251,500	315,865
Tangible Book Value Per Share	3208.36	3159.10	3743.01	3836.52	3672.83	4486.82
Land	92,875	92,875	92,875	92,875	71,163	87,160
Buildings	51,499	51,450	50,602	50,602	50,577	55,031
Machinery	48,976	48,406	48,080	46,343	46,030	47,571
Construction In Progress	111.75	-	76.21	-	52.2	130.2

Source: S&P Capital IQ. Standard template. Financial Sources.